Fluicell AB stock analysis
Fluicell AB (5J90) Stock Price & Analysis
5J90 Stock Chart & Stats
- Day’s Range
- EUR 2.38 - EUR 2.46
- 52-Week Range
- EUR 0.72 - EUR 5.22
- Previous Close
- EUR 2.49
- Volume
- N/A
- Average Volume (3M)
- 33
- Market Cap
- EUR 3.42M
- Enterprise Value
- EUR 43.46M
- Total Cash (Recent Filing)
- EUR 30.00K
- Total Debt (Recent Filing)
- EUR 2.00M
- Price to Earnings (P/E)
- 14.0
- Beta
- -0.65
- Next Earnings
- Nov 13, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability Inflection
The strong TTM revenue increase alongside positive EBIT and net income marks a meaningful operating inflection. If growth continues, expanding revenue can improve fixed-cost absorption and provide a more durable earnings base than the company’s prior loss-making periods.
Very High Gross Margin
A gross margin near 91.6% indicates substantial value captured from Fluicell’s products and technology relative to direct costs. Maintaining this level would give the company room to fund research, commercial expansion, and operating expenses as the revenue base develops.
Modest Leverage And Equity Base
Low leverage and a substantial equity base provide financial flexibility compared with a highly debt-funded structure. This balance-sheet support may help Fluicell absorb operating volatility and pursue development or commercialization without relying primarily on additional borrowing.
Bears Say
Negative Cash Generation
The company is not yet self-funding despite reporting positive net income. Negative operating cash flow and materially negative free cash flow can require continued financing, limiting flexibility and making execution of growth plans more dependent on external capital.
Persistent Historical Losses
The recent profitable TTM period has not yet established a long record of repeatable returns. Persistent historical losses and negative annual returns on equity indicate that capital has not consistently generated profits, increasing the risk that the turnaround may not endure.
Profitability Durability Risk
Fluicell’s recent profitability is encouraging but remains unproven across a longer operating history. For a small biotechnology company, margin volatility as revenue scales could weaken earnings quality and make future results less predictable than the latest TTM figures suggest.
5J90 FAQ
What was Fluicell AB’s price range in the past 12 months?
What is Fluicell AB’s market cap?
When is Fluicell AB’s upcoming earnings report date?
How were Fluicell AB’s earnings last quarter?
Is Fluicell AB overvalued?
Does Fluicell AB pay dividends?
What is Fluicell AB’s EPS estimate?
How many shares outstanding does Fluicell AB have?
What happened to Fluicell AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Fluicell AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Fluicell AB
Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carolina Trjulja
- Employees
- 11
- Website
- www.fluicell.com
- Address
- Flöjelbergsgatan 8C, Mölndal, VG, 431 37, SE
Fluicell AB (5J90) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 3 | 9 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 8 | 0 | 4 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| SE:XINTXintela AB | ||
| SE:BIOVIC.BBiovica International AB Class B | ||
| SE:NXTCLNextCell Pharma AB | ||
| SE:BIOWKSBio-Works Technologies AB | ||
| SE:FLUOFluoGuide A/S |

